Nuvectis Pharma Inc (NVCT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Nuvectis Pharma Inc (NVCT) has a cash flow conversion efficiency ratio of -0.499x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.53 Million) by net assets ($9.08 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Nuvectis Pharma Inc worth for the company's overall valuation and market capitalisation.
Nuvectis Pharma Inc - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Nuvectis Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Nuvectis Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nuvectis Pharma Inc ranked by their cash flow conversion efficiency. See NVCT debt coverage from operations to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shenzhen Jieshun Science and Technology Industry Co Ltd
SHE:002609
|
0.059x |
|
Center Laboratories
TWO:4123
|
0.002x |
|
Citic Guoan Wine Co Ltd
SHG:600084
|
0.005x |
|
Ability Enterprise Co Ltd
TW:2374
|
-0.010x |
|
Astria Therapeutics Inc
NASDAQ:ATXS
|
-0.138x |
|
Fineotex Chemical Limited
NSE:FCL
|
0.021x |
|
HELL.UNSP.ADR A1 DL-0001
F:1MO
|
0.050x |
|
PWR Holdings Ltd
AU:PWH
|
0.100x |
Annual Cash Flow Conversion Efficiency for Nuvectis Pharma Inc (2020–2025)
The table below shows the annual cash flow conversion efficiency of Nuvectis Pharma Inc from 2020 to 2025. View today's stock price for Nuvectis Pharma Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $18.41 Million | $-16.01 Million | -0.869x | +31.05% |
| 2024-12-31 | $9.71 Million | $-12.25 Million | -1.261x | +3.57% |
| 2023-12-31 | $12.20 Million | $-15.95 Million | -1.308x | -37.12% |
| 2022-12-31 | $14.22 Million | $-13.56 Million | -0.954x | -210.45% |
| 2021-12-31 | $-11.01 Million | $-9.50 Million | 0.863x | +23811.81% |
| 2020-12-31 | $6.65 Million | $24.00K | 0.004x | -- |
About Nuvectis Pharma Inc
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was forme… Read more